eicosapentaenoic acid ethyl ester has been researched along with Nerve Degeneration in 2 studies
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
Excerpt | Relevance | Reference |
---|---|---|
"The Unified Huntington's Disease Rating Scale (UHDRS) was used for assessment." | 2.71 | Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. ( Greenamyre, JT; Hayden, MR; Hersch, S; Horrobin, DF; Leavitt, BR; Manku, M; Murck, H; Puri, BK; Rosenblatt, A; Ross, CA; Sword, A; Vaddadi, KS, 2005) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Puri, BK | 1 |
Leavitt, BR | 2 |
Hayden, MR | 2 |
Ross, CA | 1 |
Rosenblatt, A | 1 |
Greenamyre, JT | 1 |
Hersch, S | 1 |
Vaddadi, KS | 1 |
Sword, A | 1 |
Horrobin, DF | 1 |
Manku, M | 1 |
Murck, H | 1 |
Van Raamsdonk, JM | 1 |
Pearson, J | 1 |
Rogers, DA | 1 |
Lu, G | 1 |
Barakauskas, VE | 1 |
Barr, AM | 1 |
Honer, WG | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Coenzyme Q10 in Huntington's Disease (HD)[NCT00608881] | Phase 3 | 609 participants (Actual) | Interventional | 2008-03-31 | Terminated (stopped due to Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 1.39 |
B - Placebo | 1.43 |
The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 4.29 |
B - Placebo | 5.06 |
"The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each yes reply and a score of 0 is given for each no reply (scale range is 0-25). Higher scores indicate better functioning." (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -7.93 |
B - Placebo | -8.02 |
The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -26.30 |
B - Placebo | -24.86 |
Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -14.21 |
B - Placebo | -14.51 |
Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -7.57 |
B - Placebo | -8.61 |
Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -15.25 |
B - Placebo | -19.13 |
The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -10.95 |
B - Placebo | -11.36 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -4.53 |
B - Placebo | -4.76 |
The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 18.06 |
B - Placebo | 19.18 |
The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -5.07 |
B - Placebo | -4.47 |
The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
Intervention | rank (Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 303.3 |
B - Placebo | 306.7 |
(NCT00608881)
Timeframe: 5 years
Intervention | participants completing study on drug (Number) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 98 |
B - Placebo | 108 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
Intervention | days to event (Median) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 917 |
B - Placebo | 911 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
Intervention | days to event (Median) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 553 |
B - Placebo | 549 |
1 trial available for eicosapentaenoic acid ethyl ester and Nerve Degeneration
Article | Year |
---|---|
Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Apoptosis; Brain; Cohort Studies; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; | 2005 |
1 other study available for eicosapentaenoic acid ethyl ester and Nerve Degeneration
Article | Year |
---|---|
Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease.
Topics: Animals; Behavior, Animal; Cell Count; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphopr | 2005 |